BioCryst Pharmaceuticals, Inc.
@BioCrystPharma
Followers
2K
Following
16
Media
173
Statuses
352
We develop oral small-molecule & protein therapeutics for hereditary angioedema (HAE) & other rare diseases. Community guidelines: https://t.co/HJsf9ax79K.
Durham, North Carolina
Joined July 2012
The FDA approval of our prophylactic therapy for children aged 2 to <12 with hereditary angioedema marks a transformative moment for families who live with HAE and the physicians who treat the condition. https://t.co/XuEyFPJ2l2
0
0
1
We are proud to announce that the US FDA approved our prophylactic therapy for the treatment of hereditary angioedema (HAE) in children aged 2 to <12 years. https://t.co/XuEyFPJ2l2
0
1
7
Today we announced the presentation of new data at the @ACAAI 2025 Annual Scientific Meeting. Stop by our poster sessions to learn more. #ACAAI25
https://t.co/Hmvygfqbcb
0
0
0
We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field at the @ACAAI 2025 Annual Scientific Meeting https://t.co/GxLPPCfppS
#ACAAI25
0
0
0
Today we announced that we will acquire Astria Therapeutics. Read more: https://t.co/pPLenb0BKf
1
0
1
Today we announced that Charlie Gayer will succeed Jon Stonehouse as Chief Executive Officer upon his retirement in December. https://t.co/CIyIDUmtRG
1
0
2
We are excited to be attending the 2025 @US_HAEA National Summit in Baltimore and looking forward to connecting with the #HAE community. https://t.co/zhMf4gQOuu
0
0
0
We are excited to announce that Babar Ghias joins BioCryst as our new Chief Financial Officer and Head of Corporate Development. https://t.co/9DAgzOZSlT
0
0
1
Today we announced the sale of our European business to Neopharmed Gentili. Read more: https://t.co/s53BARmOLI
0
0
4
We presented new data at the European Academy of Allergy and Clinical Immunology (@EAACI_HQ) Congress 2025: https://t.co/4DDba7BjnT
#EAACI2025
0
0
0
We are looking forward to connecting with the #HAE community and presenting new data at the European Academy of Allergy and Clinical Immunology (@EAACI_HQ) Congress 2025: https://t.co/hj67fhnbEg
#EAACI2025
0
0
0
Today we announced the presentation of new data at the C1-Inhibitor Deficiency & Angioedema Workshop in Budapest. https://t.co/iwG8JQsGyo
0
0
1
We presented at the @ISPORorg Patient-Centered Research Summit 2025 this week, sharing real-world evidence. https://t.co/ktoeSF6Cd2
0
0
2
We're pleased to announce the FDA acceptance of our New Drug Application for our oral prophylactic therapy for patients with hereditary angioedema (#HAE) aged 2 to 11 years. https://t.co/x1mx3ldA8v
0
0
4
Today we announced the appointment of healthcare investment banking leader, Steve Frank, to our board of directors. Read more: https://t.co/M1SHbzrx28
0
0
2
Our new US Medical Affairs website will enhance our engagement with the scientific community by providing access to scientific content, covering resources to meet the needs of health care practitioners. If you're a US based healthcare practitioner, click: https://t.co/rW4PKohANV
0
1
1
We will be presenting at The American Academy of Allergy, Asthma & Immunology's (@AAAAI_org) 2025 Annual Meeting taking place at in San Diego, from February 28 – March 3 #AAAAI25
https://t.co/1rDHJ9SmMX
1
0
3
We’re looking forward to connecting with the #HAE community and those in the allergy and immunology field in at #AAAAI25. https://t.co/b69nOOqeYd
@AAAAI_org
1
0
1
0
0
0
Mark your calendar – BioCryst will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th at 3:00pm PT/6:00pm ET. Learn more: https://t.co/IwgC9otW5z
#JPMHC25
0
0
1